- Oral cavity mucosa damage after chemotherapy and mTOR inhibitors treatment2015 | Faculty of Medicine in Pilsen
- MTOR - the atractive and mysterious signal proteinPublication without faculty affiliation
- CAS mediates crosstalk of Src and mTOR signalingPublication without faculty affiliation
- Activity of c-Src as a novel target for the inhibition of mTOR signaling in human diseasesPublication without faculty affiliation
- Involvement of c-Src activity in the mTOR-dependent oncogenicity of melanoma cellsPublication without faculty affiliation
- mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis2022 | First Faculty of Medicine
- Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021)2022 | Publication without faculty affiliation
- Frentizole derivatives with mTOR inhibiting and senomorphic properties2023 | Third Faculty of Medicine
- Somatostatin analog and mTOR inhibitor treatment of Merkel cell tumor2012 | Faculty of Medicine in Hradec Králové
- Treatment of gastrointestinal stromal tumours2010 | Second Faculty of Medicine
- Stomatitis in mtor inhibitors treatment and other targeted cancer therapy, possibilities of influencing it, and the use of local corticotherapy2020 | Faculty of Medicine in Pilsen
- Src-dependent activation of the mTOR signaling in melanoma cells2012 | First Faculty of Medicine
- Antibiotic immunosuppressants2008 | Second Faculty of Medicine
- Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma2023 | First Faculty of Medicine
- Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells2008 | First Faculty of Medicine
- Involvement of mTOR Pathways in Recovery from Spinal Cord Injury by Modulation of Autophagy and Immune Response2021 | Second Faculty of Medicine
- mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus2021 | First Faculty of Medicine, Faculty of Science, Faculty of Physical Education and Sport, Central Library of Charles University
- Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity2023 | Faculty of Medicine in Pilsen
- Oral mucositis in cancer patients2015 | Faculty of Medicine in Pilsen
- News in the systemic treatment of advanced kidney cancer2016 | Publication without faculty affiliation
- Systemic therapy for advanced clear cell renal cell carcinoma in 20132014 | Publication without faculty affiliation
- TSC/mTOR pathway mutation associated eosinophilic/oncocytic renal neoplasmsm: a heterogeneous group of tumors with distinct morhpology, immunohistochemical profile, and similar genetic background2022 | Faculty of Medicine in Pilsen
- The Role of Green Tea Catechin Epigallocatechin Gallate (EGCG) and Mammalian Target of Rapamycin (mTOR) Inhibitor PP242 (Torkinib) in the Treatment of Spinal Cord Injury2023 | Second Faculty of Medicine
- Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR Pathway2014 | Faculty of Medicine in Pilsen
- Kidney cancer. What is the next step after failure of treatment with angiogenesis inhibitors?2010 | Second Faculty of Medicine
- Strategies for managing endocrine resistance in advanced hormone receptor-positive and HER2-negative breast cancer2017 | First Faculty of Medicine
- New trends in renal nagiomyolipomas therapy2015 | Faculty of Medicine in Pilsen
- Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients2022 | First Faculty of Medicine
- Non-apoptotic FAS signaling controls mTOR activation and extrafollicular maturation in human B cells2024 | Second Faculty of Medicine